Informa
기조 세션

Jochen Salfeld, PhD

표적과 치료법:휴미라 등의 세포괴사인자(TNF) 안타고니스트로부터 얻은 정보

AbbVie Bioresearch Center

Tomoyuki Igawa, Ph.D.

항체 엔지니어링 기술이 촉진하는 Drug Discovery

Chugai Pharmabody Research Pte. Ltd., Singapore

Junichi Koga, Ph.D.

항체약물결합체, 이중특이성항체, 세포치료제, 종양용해성 바이러스 요법:Daiichi Sankyo에 의한 혁신적 치료법 개발의 진전과 파이프라인

Daiichi Sankyo, Japan

Kouhei Tsumoto, PhD

항체의 친화성을 높이는 방법

The University of Tokyo

2월 26일
Show Filter
08:00 - 09:00 60 mins
등록, 커피
09:00 - 09:15 15 mins
Pre-Conference Workshop
워크샵 의장 개회사
  • Sai Reddy, PhD - Assistant Professor, Department of Biosystems Science & Engineering, ETH Zurich
  • David Johnson, PhD, MBA - Founder and CEO, GigaGen, Inc.
09:15 - 09:45 30 mins
Pre-Conference Workshop
항체의 발견과 엔지니어링을 향한 게노믹스와 효모 디스플레이
  • David Johnson, PhD, MBA - Founder and CEO, GigaGen, Inc.
09:45 - 10:15 30 mins
Info
Pre-Conference Workshop
계산적 방법과 실험적 방법의 통합에 의한 항체 설계와 엔지니어링
  • Karthik Viswanathan, Ph.D. - Director, Research, Visterra, Inc.

Over the last decade there have been significant advances in computational protein design methods, high throughput protein characterization, and availability of antibody repertoire data. Convergence of these methods enable structure-guided design and engineering of antibodies. Here we discuss, through examples, application of computational and experimental methods for lead antibody discovery.

10:15 - 10:45 30 mins
Info
Pre-Conference Workshop
항체 클론의 합리적 선택
  • Hiroki Shirai, PhD - Executive Fellow, Modaility Research Laboratories Astellas Pharma

In silico sequence analysis is useful for the rational selection of developable, manufacturable, and "designable" clones. By using our high-resolution antibody modeling protocol which proved competitive at antibody modeling assessment II, we have recently found that one can identify the clones which are relatively easy for successful optimization. Molecular simulation and informatics approaches revealed such "design-ability" corresponds to structural versatility of CDR-H3.

10:45 - 11:15 30 mins
Pre-Conference Workshop
네트워킹 브레이크
11:15 - 11:45 30 mins
Info
Pre-Conference Workshop
면역 레퍼토리의 신속한 기능적 심문 - 차세대 항체 탐색법
  • Gabriel Cheung, PhD - Senior Director, BioMedicine Design, Pfizer

Numerous disruptive technologies, from NGS of BCRs to bottom-up serum Ig proteomic, have been developed to study B cell repertoires in the past decade. At Pfizer, we are further pushing the boundary of technologies to enable fast and comprehensive interrogation of functionally relevant, antigen specific B cells from both peripheral and bone marrow compartments through the use of proprietary high-throughput automation, novel single cell technology and deep sequencing.

11:45 - 12:15 30 mins
Info
Pre-Conference Workshop
차세대 시퀀싱 기술을 이용한 인간 B세포 수용체의 면역 프로파일링
  • Junho Chung, M.D., Ph.D. - Professor, Seoul National University College of Medicine

Next-generation sequencing (NGS) has allowed a massive increase in capacity to

sequence genomes at relatively low cost and in a short time frame. It has revolutionized

multiple aspects of biological research and is actively being adopted into profiling

human B cell receptor (BCR) repertoires. Several NGS platforms are currently available,

with average read lengths of 75 bp to 8,500 bp and different error rates. Using NGS, we

successfully constructed database of BCR repertoire from human volunteers. Afterwards,

we developed algorithms for analyzing the diversity, enrichment pattern, accumulation

of somatic hyper-mutation in BCR repertoire. Through in silico analysis with machine

learning technology we devised strategies to select clones of interest. Now we are actively

applying this technology for the analysis of BCR repertoire in cancer patients.

12:15 - 12:45 30 mins
Info
Pre-Conference Workshop
하이스루풋(High Throughput) 기능적 스크리닝에 의한 이중특이성항체의 표적 발견
  • Pallavi Bhatta, PhD - Principal Scientist, Functional Screening, UCB

To exploit the true potential to access novel biology with bispecific antibodies, we have developed technology to facilitate unbiased target pair identification and validation through grid screening large numbers of bispecific antibodies in functional human cell assays. Combination of our antibody discovery capabilities, a novel bispecific screening format and high throughput flow cytometry or imaging enables us to screen thousands of bispecific antibodies to hundreds of antigen combinations and identify new target pairs for a defined patient phenotype. The technology and a specific example application from patient phenotyping to new target pair discovery will be described.

12:45 - 12:55 10 mins
Pre-Conference Workshop
워크샵 종료
13:55 - 14:00 5 mins
Main Conference
의장 인사
14:00 - 14:45 45 mins
Info
Main Conference
표적과 치료법: 휴미라 등의 세포괴사인자(TNF) 안타고니스트로부터 얻은 정보
  • Jochen Salfeld, PhD - Vice President, Global Biologics, AbbVie Bioresearch Center

The presentation will focus on the role of the underlying target biology for developing novel Biologics therapeutics using TNF and TNF antagonists as case study. I will discuss the evolution of Anti-TNF approaches, the history of adalimumab and will start to answer the question how to explain some of the apparent clinical differences between the Anti-TNF agents in clinical use today. In this context the learnings about TNF biology and the mechanism of action of TNF antagonists will be discussed and how those learnings impact the development of novel therapeutics.

14:45 - 15:30 45 mins
Info
Main Conference
항체 엔지니어링 기술이 촉진하는 Drug Discovery
  • Tomoyuki Igawa, Ph.D. - CEO and Research Head, Chugai Pharmabody Research Pte. Ltd., Singapore

Previously, antibody engineering was mainly applied to improve the properties of a parent antibody by methods such as humanization, affinity maturation, stability engineering and half-life extension. Recent advances in antibody engineering have enabled us to conceive and realize novel antibody drug concepts. This presentation describes how antibody engineering technologies can drive the discovery of innovative antibody drugs.

15:30 - 16:00 30 mins
네트워킹 브레이크
16:00 - 16:30 30 mins
Main Conference
항체약물결합체, 이중특이성항체, 세포치료제, 종양용해성 바이러스 요법:Daiichi Sankyo에 의한 혁신적 치료법 개발의 진전과 파이프라인
  • Junichi Koga, PhD - Head of R&D Division, Executive Officer, Daiichi Sankyo
16:30 - 17:00 30 mins
Info
Main Conference
항체의 친화성을 높이는 방법
  • Kouhei Tsumoto, PhD - Professor and Director, The University of Tokyo


Physicochemical approaches deepen our insights into antigen-antibody interactions. Recently, we have investigated how we can rationally improve the affinity of antibodies for the targets. Here I introduce our recent progress on engineering affinity of antibody based on physical biochemical approaches.

18:00 - 19:00 60 mins
Info
네트워킹 디너

Network with fellow Antibody Engineering & Therapeutics Asia attendees from around the world by attending this Networking Dinner event at S Tokyo restaurant. Sign up to attend this optional dinner by selecting this dinner option during registration (additional fee required)

08:00 - 09:00

등록, 커피

More
Showing of Streams
Showing of Streams
15:30 - 16:00

네트워킹 브레이크

More
Showing of Streams
18:00 - 19:00
Info

네트워킹 디너

Network with fellow Antibody Engineering & Therapeutics Asia attendees from around the world by attending this Networking Dinner event at S Tokyo restaurant. Sign up to attend this optional dinner by selecting this dinner option during registration (additional fee required)

More

* 주최측 사정에 따라 사전 예고없이 프로그램이 변경될 수 있습니다.